Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies
Cancers of unknown primary (CUP) exhibit significant cellular heterogeneity and malignancy, which poses significant challenges for diagnosis and treatment. Recent years have seen deeper insights into the imaging, pathology, and genetic characteristics of CUP, driven by interdisciplinary collaboratio...
| Hlavní autoři: | , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
MDPI AG
2024-02-01
|
| Edice: | Biosensors |
| Témata: | |
| On-line přístup: | https://www.mdpi.com/2079-6374/14/2/100 |
| _version_ | 1827343991653269504 |
|---|---|
| author | Xiaohui Liu Hui Jiang Xuemei Wang |
| author_facet | Xiaohui Liu Hui Jiang Xuemei Wang |
| author_sort | Xiaohui Liu |
| collection | DOAJ |
| description | Cancers of unknown primary (CUP) exhibit significant cellular heterogeneity and malignancy, which poses significant challenges for diagnosis and treatment. Recent years have seen deeper insights into the imaging, pathology, and genetic characteristics of CUP, driven by interdisciplinary collaboration and the evolution of diagnostic and therapeutic strategies. However, due to their insidious onset, lack of evidence-based medicine, and limited clinical understanding, diagnosing and treating CUP remain a significant challenge. To inspire more creative and fantastic research, herein, we report and highlight recent advances in the diagnosis and therapeutic strategies of CUP. Specifically, we discuss advanced diagnostic technologies, including 12-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) or <sup>68</sup>Ga-FAPI (fibroblast activation protein inhibitor) PET/CT, liquid biopsy, molecular diagnostics, self-assembling nanotechnology, and artificial intelligence (AI). In particular, the discussion will extend to the effective treatment techniques currently available, such as targeted therapies, immunotherapies, and bio-nanotechnology-based therapeutics. Finally, a novel perspective on the challenges and directions for future CUP diagnostic and therapeutic strategies is discussed. |
| first_indexed | 2024-03-07T22:39:31Z |
| format | Article |
| id | doaj.art-40421b51d0fe47b48fc0e4fc07eb87e5 |
| institution | Directory Open Access Journal |
| issn | 2079-6374 |
| language | English |
| last_indexed | 2024-03-07T22:39:31Z |
| publishDate | 2024-02-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biosensors |
| spelling | doaj.art-40421b51d0fe47b48fc0e4fc07eb87e52024-02-23T15:09:35ZengMDPI AGBiosensors2079-63742024-02-0114210010.3390/bios14020100Advances in Cancer Research: Current and Future Diagnostic and Therapeutic StrategiesXiaohui Liu0Hui Jiang1Xuemei Wang2State Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, ChinaState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, ChinaState Key Laboratory of Digital Medical Engineering, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, ChinaCancers of unknown primary (CUP) exhibit significant cellular heterogeneity and malignancy, which poses significant challenges for diagnosis and treatment. Recent years have seen deeper insights into the imaging, pathology, and genetic characteristics of CUP, driven by interdisciplinary collaboration and the evolution of diagnostic and therapeutic strategies. However, due to their insidious onset, lack of evidence-based medicine, and limited clinical understanding, diagnosing and treating CUP remain a significant challenge. To inspire more creative and fantastic research, herein, we report and highlight recent advances in the diagnosis and therapeutic strategies of CUP. Specifically, we discuss advanced diagnostic technologies, including 12-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) or <sup>68</sup>Ga-FAPI (fibroblast activation protein inhibitor) PET/CT, liquid biopsy, molecular diagnostics, self-assembling nanotechnology, and artificial intelligence (AI). In particular, the discussion will extend to the effective treatment techniques currently available, such as targeted therapies, immunotherapies, and bio-nanotechnology-based therapeutics. Finally, a novel perspective on the challenges and directions for future CUP diagnostic and therapeutic strategies is discussed.https://www.mdpi.com/2079-6374/14/2/100cancers of unknown primary (CUP)diagnosticstargeted therapybio-nanotechnologyartificial intelligence (AI)microfluidic |
| spellingShingle | Xiaohui Liu Hui Jiang Xuemei Wang Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies Biosensors cancers of unknown primary (CUP) diagnostics targeted therapy bio-nanotechnology artificial intelligence (AI) microfluidic |
| title | Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies |
| title_full | Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies |
| title_fullStr | Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies |
| title_full_unstemmed | Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies |
| title_short | Advances in Cancer Research: Current and Future Diagnostic and Therapeutic Strategies |
| title_sort | advances in cancer research current and future diagnostic and therapeutic strategies |
| topic | cancers of unknown primary (CUP) diagnostics targeted therapy bio-nanotechnology artificial intelligence (AI) microfluidic |
| url | https://www.mdpi.com/2079-6374/14/2/100 |
| work_keys_str_mv | AT xiaohuiliu advancesincancerresearchcurrentandfuturediagnosticandtherapeuticstrategies AT huijiang advancesincancerresearchcurrentandfuturediagnosticandtherapeuticstrategies AT xuemeiwang advancesincancerresearchcurrentandfuturediagnosticandtherapeuticstrategies |